Second-Line Therapy After Enfortumab Vedotin and Pembrolizumab: A Dilemma That Didn't Exist Before
First-line treatment has moved so far ahead of second-line evidence that this exact sequencing question didn't exist before enfortumab vedotin plus pembrolizumab became standard — and the option that would have fit her best was withdrawn from the market before she needed it.
M.R., a 59-year-old woman, has spent the last year juggling her metastatic bladder cancer diagnosis alongside caring for her mother, who moved into her home following a stroke — a responsibility she's kept up through every cycle of therapy so far without missing a caregiving shift, by her own insistence. She received enfortumab vedotin plus pembrolizumab as first-line therapy nine months ago per the current EV-302-based standard, with an initial partial response, but restaging imaging now shows unambiguous progression in her retroperitoneal nodes and a new liver lesion. This is a treatment-sequencing situation that, before EV-302 changed the first-line standard, essentially didn't exist: platinum-based chemotherapy used to be first-line therapy itself, not a second-line option being considered after a different regimen's failure.
Until eighteen months ago there would have been two options here. Platinum-based chemotherapy, effectively repositioned to second-line by the new first-line standard, has a long track record, though using it after enfortumab vedotin rather than before is a sequencing pattern with far less direct outcomes data than the reverse order. The other was sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate granted accelerated approval in 2021 on TROPHY-U-01's response-rate data — an approval its manufacturer voluntarily withdrew in October 2024 after the confirmatory phase 3 TROPiCS-04 trial missed its primary overall survival endpoint and reported more deaths from adverse events than the control arm, concentrated early and driven by neutropenic complications. The option whose toxicity profile would have suited her best is precisely the one no longer available to her. She already carries mild, residual grade 1 neuropathy from her enfortumab vedotin course, numbness in her fingertips that makes some of her mother's finer care tasks — managing pill organizers, buttoning shirts — harder than they used to be, and she has said directly that a treatment schedule she can plan her caregiving shifts around matters to her nearly as much as which drug is more likely to work. Her tumor has been sent for sequencing, and an FGFR alteration would open erdafitinib as a genuinely targeted alternative; that result is not back yet, which makes the timing of it, rather than a choice between two drugs both on the shelf, the thing the team is actually arguing about.
Second-line therapy, a sequencing question that didn't used to exist
I'd start platinum-based chemotherapy now. She's cisplatin-eligible, it has the longest track record of anything still available to her, and the sequencing question — using it after enfortumab vedotin rather than before — is a gap in outcomes data, not a reason to think it stops working. Sacituzumab govitecan would have been the natural second option two years ago; TROPiCS-04 took it off the table, and I don't want to spend time waiting on a sequencing result while she has a new liver lesion.
I'd hold ten days for the sequencing result, and I want to be specific about why rather than resting on general caution. THOR showed erdafitinib beating chemotherapy on overall survival in FGFR-altered urothelial carcinoma after prior checkpoint inhibition — which is precisely her treatment history. If she comes back FGFR-altered, starting a platinum today spends a line of therapy on the weaker option and adds cisplatin's own sensory toxicity to fingertips already numb enough to make her mother's pill organizer difficult.
I'm not dismissing the liver lesion — ten days is not nothing. But you're treating the delay as the only cost in play, and a wasted line of therapy in a woman with residual neuropathy is the larger one.
Agreed: FGFR sequencing expedited, with cisplatin-gemcitabine to start the moment the result returns FGFR wild-type, and erdafitinib substituted if it does not. Growth-factor support and formal neuropathy grading built into either arm from cycle one.
Not agreed, and named explicitly as unresolved rather than settled by today's individualized choice:
Would treat visible progression as the governing fact and start platinum immediately in a similar future patient, sending sequencing alongside rather than waiting on it.
Would make molecular results a prerequisite rather than a parallel step in any post-EV patient, on the grounds that a second line is now scarce enough that spending one on the wrong drug is the costlier error.
Both noted that the disagreement itself is a product of how thin this line has become: the withdrawal of sacituzumab govitecan removed the option that would have suited her toxicity profile best, and neither physician treated the remaining choice as a satisfactory substitute for the one TROPiCS-04 closed off.